Pentetrazole (Cardiazol) veterinary-grade crystalline API, with a published melting point near 59 °C, is formulated into a 100 mg/mL (10.0% w/v) sterile solution for intravenous or subcutaneous administration in equine anesthesia recovery and companion animal respiratory depression. Dissolution of the API is completed in a 50 L jacketed stainless steel vessel equipped with a bottom-mounted magnetic stirrer running at 150 rpm for 15 min at 25 °C, using Water for Injection containing 0.9% w/v sodium chloride and pH adjusted to 5.5–6.5 with 0.1 N hydrochloric acid or sodium hydroxide. A 50 L batch consumes 5.0 kg of API. The solution is clarified through a 0.45 µm polypropylene prefilter and sterilized by filtration through a 0.22 µm PVDF membrane into amber Type I borosilicate vials under nitrogen overlay. Terminal moist-heat sterilization at 121 °C for 15 min is not universally validated because published thermal degradation data for this specific configuration is limited; therefore aseptic filling with a sterility assurance level of 10⁻⁶ is used under Ph. Eur. 5.1.2 and USP <71>. Filling line temperature is maintained below 25 °C to avoid localized softening of the low-melting API on needle tips. Filter integrity is confirmed by pressure decay or bubble point before and after filling. Release controls include assay by HPLC per Ph. Eur. 2.2.29, pH per Ph. Eur. 2.2.3, particulate matter per USP <788>, and sterility per Ph. Eur. 2.6.1. Regulatory compliance in the European Union falls under Regulation (EU) 2019/6; for food-producing species, the absence of a maximum residue limit under Regulation (EU) No 37/2010 restricts use to non-food animals or requires a positive list entry and validated withdrawal period. Finished presentations are 50 mg/mL and 100 mg/mL solutions in 20 mL and 50 mL multi-dose vials, with single-dose configurations used where preservative compatibility has not been established.

What limits dose uniformity in low-dose oral tablet and capsule manufacture?

Low-dose oral solids containing 25 mg to 100 mg pentetrazole per unit are manufactured by direct compression or wet granulation depending on the particle size distribution and flow properties of the API. The principal processing conflict is segregation of the low-dose active under vibration and hopper discharge, which is controlled by micronizing the API and using a geometric pre-blend before final lubrication. A 50 mg tablet with a total core mass of 120 mg places the API at 41.7% w/w, while a 50 mg capsule filled to 200 mg yields 25.0% w/w. Direct compression formulations contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate; croscarmellose sodium is maintained below 5.0% w/w to limit excessive moisture wicking that can destabilize the low-melting API during storage. Compression is performed on a 10-station rotary press using 6 mm round concave tooling at 5–8 kN force, targeting tablet hardness of 4–7 kp and friability below 1.0% per USP <1216>. Capsule filling uses a dosing-disc or tamping-pin machine with size 3 hard gelatin capsules. Dissolution testing is conducted in 900 mL of 0.1 N hydrochloric acid using USP apparatus 2 at 50 rpm, with acceptance criteria aligned to USP <711> and Ph. Eur. 2.9.3. Content uniformity must conform to USP <905> or Ph. Eur. 2.9.40, and the manufacturing suite operates under 21 CFR 211. Because published dissolution profiles for pentetrazole oral solids are limited, each specification requires product-specific validation and in-process blend uniformity trending across 10 sampling points. Finished products include 50 mg and 100 mg tablets and 25 mg and 50 mg capsules for use under veterinary prescription.

For water-soluble oral powders and granules intended for neonatal intensive care units and farrowing facilities, the API is first micronized to a particle size distribution where D90 ≤ 75 µm to improve dissolution rate and content uniformity. The formulation contains 10.0% w/w micronized API, dextrose monohydrate, citric acid, sodium citrate, and colloidal silicon dioxide. A 250 L double-cone blender operating at 20 rpm for 20 min produces the initial dry blend; when granulated, the blend is sprayed with a 5.0% w/w aqueous povidone K30 binder solution in a fluid-bed granulator. Inlet air temperature is held below 45 °C because the API has a published melting point near 59 °C, creating a processing window of approximately ±3 °C to avoid softening, screen blinding of the 850 µm sieve, and batch-to-batch granule density variation. Granules are dried to a moisture content below 2.0% w/w and sifted with an 850 µm sieve to remove agglomerates. Each 50 g sachet delivers 5.0 g of API; reconstitution at 1.0 g/L in drinking water yields 100 mg/L. Compliance requires Ph. Eur. 2.9.5 for uniformity of mass of single-dose preparations, Ph. Eur. 2.9.12 for particle size distribution, and USP <905> where content uniformity is adopted. Manufacture follows 21 CFR 211; for food-producing animals, the veterinarian must confirm that pentetrazole is permitted under the applicable positive list or that the cascade provision in Article 112 of Regulation (EU) 2019/6 applies, because no EU MRL has been established under Regulation (EU) No 37/2010. Terminal products include 10.0% w/w oral powder in 50 g and 100 g sachets and granules in 500 g bottles.

Premix blending, carrier selection, and carryover control

Manufacture of a 2.0% w/w active premix begins with stepwise geometric dilution of micronized pentetrazole into lactose monohydrate or corn cob carrier with a particle size range of 200–500 µm. A 500 L horizontal ribbon blender filled to 60% of working capacity is run at 25 rpm for 15 min; fill volumes below 50% create dead zones near the ribbon shaft, while volumes above 70% reduce shear and prolong blending time. API homogeneity is confirmed by sampling 10 locations and requiring a coefficient of variation below 5.0%. The inclusion rate of 5.0 kg premix per tonne of finished feed delivers 100 mg/kg feed, assuming a 2.0% w/w active premix. Carryover control requires validated cleaning procedures, rinse and swab sampling, and residual API limits derived from toxicological thresholds; equipment contact surfaces are inspected after each batch to prevent cross-concentration drift in subsequent non-medicated feed. Regulatory oversight for medicated feed premises falls under 21 CFR 225 in the United States and Regulation (EU) 2019/6, Annex II in Europe. Release testing includes appearance, assay, loss on drying, and uniformity per Ph. Eur. 2.9.5 or an equivalent compendial method. In jurisdictions where pentetrazole lacks an MRL for food-producing species, the premix must be labeled for non-food animals or restricted to companion animal use. Terminal products include 2.0% w/w premix in 25 kg multi-wall paper bags and 0.5% w/w premix for feed mills requiring lower active concentration.

Lyophilized pentetrazole for reconstitution is manufactured as a sterile, amorphous cake by freezing a filtered solution containing the API and mannitol at a 1:2 w/w ratio. A 50 mg/mL API solution with 100 mg/mL mannitol is filtered through a 0.22 µm membrane and filled at 2 mL into 10 mL Type I glass vials, resulting in a nominal 100 mg API charge and 300 mg total solids per vial. The collapse temperature of the formulation must be determined by freeze-drying microscopy before cycle validation; if the primary drying shelf temperature exceeds the collapse temperature, the cake shrinks, reconstitution time increases, and residual moisture rises. The lyophilization cycle includes freezing at -40 °C for 4 h, primary drying at a shelf temperature of -10 °C and chamber pressure of 0.08 mbar for 24 h, and secondary drying at 25 °C for 6 h. Residual moisture is controlled below 1.0% w/w by Karl Fischer titration per Ph. Eur. 2.5.12. Reconstitution with 2 mL Water for Injection yields a 50 mg/mL solution. Compliance requirements include USP <71> sterility testing, Ph. Eur. 2.9.19 particulate contamination, and USP <922> water activity where moisture mapping is used. Aseptic processing is performed under 21 CFR 211 and equivalent EU GMP. Because lyophilization is suitable for heat-sensitive actives, this presentation is used when terminal sterilization is not validated. Terminal products include 100 mg per vial lyophilized powder for injection, packed in 10-vial cartons.

When a concentrated sterile solution is preferred over multi-dose vials

A 200 mg/mL (20.0% w/v) concentrated sterile solution is filled into 5 mL single-dose amber ampoules under nitrogen overlay for dilution by the veterinarian before slow intravenous injection. The solution is compounded in Water for Injection, adjusted to pH 5.0–6.5, and sterilized by double-stage membrane filtration through 0.45 µm and 0.22 µm filters into a Class A filling zone. Dilution of 1 part concentrate with 3 parts of 0.9% w/v sodium chloride yields a 50 mg/mL injectable solution. Release testing follows USP <788> for particulate matter, Ph. Eur. 2.9.19 for sub-visible particles, and USP <1> injections general chapter for volume in container. The product meets sterility expectations under Ph. Eur. 5.1.2 and is manufactured under 21 CFR 211. Because the API has a low published melting point near 59 °C, the filling line temperature is maintained below 25 °C to avoid localized softening or coating of filling needles. Published data for long-term stability of 200 mg/mL pentetrazole solutions under accelerated conditions is limited, so the concentrate is intended for short-term distribution and immediate dilution. Terminal products include 200 mg/mL concentrated solution in 5 mL single-dose ampoules, with 10 ampoules per carton.